Kingworld Medicines Group Ltd

Kingworld Medicines Group Ltd has a market capitalization of 286.35 million CNY and a price-to-earnings ratio of 25.38, indicating a relatively high valuation relative to its earnings. The company's price-to-book ratio is 0.46, suggesting that the market values the company at a discount to its book value. The company's liquidity position is characterized by a current ratio of 1.09, indicating a moderate ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, Kingworld Medicines Group Ltd has a return on equity (ROE) of 1.83% and a return on assets (ROA) of 0.78%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The company's operating margin is 6.89% (calculated from operating income of 63.16 million CNY on revenue of 917.34 million CNY), which is relatively low compared to industry peers. The gross margin is 27.05% (calculated from gross profit of 247.91 million CNY on revenue of 917.34 million CNY), indicating moderate efficiency in production and cost control. The company's revenue is primarily concentrated in the Chinese market, with no significant international exposure disclosed in the financial data. The company operates in a single business segment, focusing on pharmaceutical products, and there is no indication of geographic diversification in the provided data. The company's revenue concentration in a single market and segment increases its exposure to local economic and regulatory risks. Kingworld Medicines Group Ltd's growth trajectory is modest, with no significant revenue growth disclosed in the financial data. The company's capital expenditures are negative at -29.64 million CNY, indicating a reduction in investment in physical assets. The company's free cash flow is 17.09 million CNY, which is relatively low and may limit its ability to reinvest in growth opportunities. The company's operating cash flow is 84.56 million CNY, which is positive but not substantial. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key risk flag is the negative net cash position after subtracting total debt, which could impact the company's ability to fund operations and meet obligations. The company's debt-to-equity ratio is 0.7, indicating a moderate level of leverage. The company has not issued additional shares recently, and there is no indication of dilution pressure in the near term. Recent events and disclosures include the company's financial performance for the latest reporting period, with a net income of 11.28 million CNY and a revenue of 917.34 million CNY. The company's last actual EPS was 0.07 CNY, and the last actual revenue was 1,053.53 million CNY according to analyst estimates. There are no recent filings or transcripts indicating significant strategic changes or new product launches.